	US 12,286,456 B2
	Purification of virus like particles
Ross Taylor, Cambridge, MA (US)
Assigned to Takeda Vaccines, Inc., Cambridge, MA (US)
Filed by Takeda Vaccines, Inc., Cambridge, MA (US)
Filed on Aug. 11, 2021, as Appl. No. 17/399,731.
Application 16/201,073 is a division of application No. 13/925,449, filed on Jun. 24, 2013, granted, now 10,167,320, issued on Jan. 1, 2019.
Application 17/399,731 is a continuation of application No. 16/201,073, filed on Nov. 27, 2018, granted, now 11,091,519, issued on Aug. 17, 2021.
Claims priority of provisional application 61/794,086, filed on Mar. 15, 2013.
Claims priority of provisional application 61/663,218, filed on Jun. 22, 2012.
Prior Publication US 2022/0213147 A1, Jul. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); C12N 7/00 (2006.01)

CPC C07K 14/005 (2013.01) [C12N 7/00 (2013.01); C12N 2710/14143 (2013.01); C12N 2770/16022 (2013.01); C12N 2770/16023 (2013.01); C12N 2770/16051 (2013.01)]

23 Claims

1. A solution comprising a purified population of human norovirus Virus-Like Particles (VLPs), wherein the norovirus VLPs comprise at least genogroup II VLPs, wherein said solution contains no more than about 80% residual contaminating protein relative to said VLPs, and wherein the genogroup II VLPs comprise less than 1% VLPs with a truncated VP1 subunit.